Bioxcel Therapeutics Stock In The News
| BTAI Stock | USD 0.57 0.02 3.39% |
Our overall analysis of BioXcel Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards BioXcel Therapeutics. The specific impact of BioXcel Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of BioXcel Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using BioXcel Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out BioXcel Therapeutics Backtesting and BioXcel Therapeutics Hype Analysis. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.
BioXcel |
BioXcel Therapeutics Today Top News and Investor Outlook
BioXcel Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide BioXcel and other traded companies coverage with news coverage. We help investors stay connected with BioXcel headlines for the 22nd of November to make an informed investment decision based on correlating the impacts of news items on BioXcel Stock performance. Please note that trading solely based on the BioXcel Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
BioXcel Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the BioXcel earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about BioXcel Therapeutics that are available to investors today. That information is available publicly through BioXcel media outlets and privately through word of mouth or via BioXcel internal channels. However, regardless of the origin, that massive amount of BioXcel data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of BioXcel Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioXcel Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioXcel Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioXcel Therapeutics alpha.
BioXcel Largest EPS Surprises
Earnings surprises can significantly impact BioXcel Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2019-08-06 | 2019-06-30 | -0.6 | -0.54 | 0.06 | 10 | ||
2019-03-07 | 2018-12-31 | -0.39 | -0.46 | -0.07 | 17 | ||
2019-11-14 | 2019-09-30 | -0.65 | -0.57 | 0.08 | 12 | ||
2019-05-07 | 2019-03-31 | -0.55 | -0.46 | 0.09 | 16 | ||
2018-05-14 | 2018-03-31 | -0.25 | -0.37 | -0.12 | 48 | ||
2022-08-09 | 2022-06-30 | -1.22 | -1.35 | -0.13 | 10 |
BioXcel Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to BioXcel Therapeutics Stock. Current markets are slightly bullish. About 58% of major world exchanges and indexes are currently up. See today's market update for more information.
21st of November 2024
BioXcel Therapeutics amends credit agreement, issues new warrants at investing.com
15th of November 2024
BioXcel Therapeutics Inc Q3 2024 Earnings Call Highlights Strategic Trials and ... at gurufocus.com
14th of November 2024
BioXcel Therapeutics Inc Reports Q3 2024 Earnings Net Revenue at 214K, Net Loss Narrows to... at gurufocus.com
8th of November 2024
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 at finance.yahoo.com
15th of October 2024
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Car... at finance.yahoo.com
4th of October 2024
BioXcel Therapeutics CSO sells shares worth 3,946 at investing.com
3rd of October 2024
Disposition of 5556 shares by Oneill Vincent of BioXcel Therapeutics at 0.55 subject to Ru... at MacroaxisInsider
23rd of September 2024
Mizuho maintains Neutral rating on BioXcel Therapeutics stock - Investing.com at news.google.com
17th of September 2024
Acquisition by Oneill Vincent of 21250 shares of BioXcel Therapeutics subject to Rule 16b-... at investing.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BioXcel Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BioXcel Therapeutics' short interest history, or implied volatility extrapolated from BioXcel Therapeutics options trading.
Check out BioXcel Therapeutics Backtesting and BioXcel Therapeutics Hype Analysis. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.04) | Revenue Per Share 0.074 | Quarterly Revenue Growth 1.416 | Return On Assets (0.64) | Return On Equity (17.67) |
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.